« Back to Record
Citation APA

Bardia, A., Tolaney, S. S., Punie, K., Loirat, D., Oliveira, M., Kalinsky, K., Zelnak, A. A., Aftimos, P., Dalenc, F., Sardesai, S. S., Hamilton, E., Sharma, P., Recalde, S., Gil, E., Traina, T. T., O'Shaughnessy, J., Cortes, J., Tsai, M. H., Vahdat, L. L., Diéras, V., Carey, L. L., Rugo, H. H., Goldenberg, D. D., Hong, Q. Q., Olivo, M. M., Itri, L. M., & Hurvitz, S. (2021). Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Annals of oncology. doi:10.1016/j.annonc.2021.06.002


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/329200

Bardia, A., Tolaney, S. S., Punie, K., Loirat, D., Oliveira, M., Kalinsky, K., Zelnak, A. A., Aftimos, P., Dalenc, F., Sardesai, S. S., Hamilton, E., Sharma, P., Recalde, S., Gil, E., Traina, T. T., O'Shaughnessy, J., Cortes, J., Tsai, M. H., Vahdat, L. L., Diéras, V., Carey, L. L., Rugo, H. H., Goldenberg, D. D., Hong, Q. Q., Olivo, M. M., Itri, L. M., & Hurvitz, S. (2021). Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Annals of oncology. doi:10.1016/j.annonc.2021.06.002